Home > Research > Publications & Outputs > Evaluation of C-reactive protein measurement fo...

Research

Links

Text available via DOI:

Keywords

View graph of relations

Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members

Research output: Contribution to Journal/Magazine › Review article › peer-review

Published

Standard

Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. / Di Napoli, Mario; Schwaninger, Markus; Cappelli, Roberto et al.
In: Stroke, Vol. 36, No. 6, 06.2005, p. 1316-1329.

Research output: Contribution to Journal/Magazine › Review article › peer-review

Harvard

Di Napoli, M, Schwaninger, M, Cappelli, R, Ceccarelli, E, Di Gianfilippo, G, Donati, C, Emsley, HCA, Forconi, S, Hopkins, SJ, Masotti, L, Muir, KW, Paciucci, A, Papa, F, Roncacci, S, Sander, D, Sander, K, Smith, CJ, Stefanini, A & Weber, D 2005, 'Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members', Stroke, vol. 36, no. 6, pp. 1316-1329. https://doi.org/10.1161/01.STR.0000165929.78756.ed

APA

Di Napoli, M., Schwaninger, M., Cappelli, R., Ceccarelli, E., Di Gianfilippo, G., Donati, C., Emsley, H. C. A., Forconi, S., Hopkins, S. J., Masotti, L., Muir, K. W., Paciucci, A., Papa, F., Roncacci, S., Sander, D., Sander, K., Smith, C. J., Stefanini, A., & Weber, D. (2005). Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke, 36(6), 1316-1329. https://doi.org/10.1161/01.STR.0000165929.78756.ed

Vancouver

Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke. 2005 Jun;36(6):1316-1329. Epub 2005 May 24. doi: 10.1161/01.STR.0000165929.78756.ed

Author

Di Napoli, Mario ; Schwaninger, Markus ; Cappelli, Roberto et al. / Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke : a statement for health care professionals from the CRP pooling project members. In: Stroke. 2005 ; Vol. 36, No. 6. pp. 1316-1329.

Bibtex

@article{092c3bd10f79488b85c159df871080d4,
title = "Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members",
abstract = "Background and Purpose - Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. Summary of Review - CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins. Conclusion - At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.",
keywords = "Aspirin, Cerebrovascular disorders, Inflammation, Meta-analysis, Mortality, Prevention, Risk factors, Scientific statements",
author = "{Di Napoli}, Mario and Markus Schwaninger and Roberto Cappelli and Elena Ceccarelli and {Di Gianfilippo}, Giacinto and Cristina Donati and Emsley, {Hedley C. A.} and Sandro Forconi and Hopkins, {Stephen J.} and Luca Masotti and Muir, {Keith W.} and Anna Paciucci and Francesca Papa and Sabina Roncacci and Dirk Sander and Kerstin Sander and Smith, {Craig J.} and Alessandro Stefanini and Daniela Weber",
year = "2005",
month = jun,
doi = "10.1161/01.STR.0000165929.78756.ed",
language = "English",
volume = "36",
pages = "1316--1329",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke

T2 - a statement for health care professionals from the CRP pooling project members

AU - Di Napoli, Mario

AU - Schwaninger, Markus

AU - Cappelli, Roberto

AU - Ceccarelli, Elena

AU - Di Gianfilippo, Giacinto

AU - Donati, Cristina

AU - Emsley, Hedley C. A.

AU - Forconi, Sandro

AU - Hopkins, Stephen J.

AU - Masotti, Luca

AU - Muir, Keith W.

AU - Paciucci, Anna

AU - Papa, Francesca

AU - Roncacci, Sabina

AU - Sander, Dirk

AU - Sander, Kerstin

AU - Smith, Craig J.

AU - Stefanini, Alessandro

AU - Weber, Daniela

PY - 2005/6

Y1 - 2005/6

N2 - Background and Purpose - Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. Summary of Review - CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins. Conclusion - At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.

AB - Background and Purpose - Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke. Summary of Review - CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins. Conclusion - At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.

KW - Aspirin

KW - Cerebrovascular disorders

KW - Inflammation

KW - Meta-analysis

KW - Mortality

KW - Prevention

KW - Risk factors

KW - Scientific statements

U2 - 10.1161/01.STR.0000165929.78756.ed

DO - 10.1161/01.STR.0000165929.78756.ed

M3 - Review article

C2 - 15879341

AN - SCOPUS:20444381235

VL - 36

SP - 1316

EP - 1329

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -